Product Development Risk from Divergence from Market Needs
First written in FY2016. 29 of 31 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2026: 14 of 29 companies on the "Worse" side.
76 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「・新製品開発、現行製品の改良、コストダウン、基礎研究分野における開発が成功しないリスク ・市場の変化を捉えきれず市場ニーズに乖離し、受け入れられないリスク」
研究開発投資の不成功及び市場ニーズとの乖離による製品開発リスクを、影響度「高」、発生可能性「中」として継続している。 - FY2025-H1RestatedAnnual report
「No new business or other risks arose during the current interim consolidated accounting period. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2024-Q1RestatedAnnual report
「No new business or other risks arose during the three months ended March 31. There were also no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2023リスク評価・対応策を具体化Annual report
「・注力領域への経営資源投入及びオープンイノベーションによる開発の加速 ・製品開発へのデジタル技術活用 ・健康機能の科学的評価の仕組みを構築し、多様なお客様の健康に寄与できる安全な製品の開発 ・デジタル人財開発による販売データ、お客様の声の分析高度化 ・外部の研究機関、スタートアップ企業との協働による開発の加速」
研究開発リスクについて、従来のリスク記載に加え、注力領域への資源投入、オープンイノベーション、デジタル技術、外部研究機関・スタートアップとの協働という対応策を体系的に示している。 - FY2023-Q3RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the third quarter. In addition, there were no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2023-Q2RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the second quarter. In addition, there were no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2023-Q1RestatedAnnual report
「No new business or other risks arose during the three months ended March 31. There were also no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2022-Q3RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the third quarter. In addition, there were no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2022-Q2RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the second quarter. In addition, there were no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2022-Q1RestatedAnnual report
「No new business or other risks arose during the three months ended March 31. There were also no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2021RestatedAnnual report
「・新製品開発、現行製品の改良、コストダウン、基礎研究分野における開発が成功しないリスク ・市場の変化をとらえきれず市場ニーズに乖離し、受け入れられないリスク」
研究開発投資の不成功及び市場ニーズとの乖離によるリスクを継続している。 - FY2021-Q3RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the third quarter. In addition, there were no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2021-Q2RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the second quarter. In addition, there were no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2021-Q1RestatedAnnual report
「No new business or other risks arose during the three months ended March 31. There were also no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2020RestatedAnnual report
「There is no guarantee that these development investments will succeed or all lead to new products. If research and development themes diverge from market needs and are not accepted, they may affect our group’s operating results and financial position.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクを継続して記載している。 - FY2020-Q3RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the third quarter. In addition, there were no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2020-Q2RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the second quarter. In addition, there were no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2020-Q1RestatedAnnual report
「No new business or other risks arose during the three months ended March 31. There were also no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2019-Q3RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the second quarter. In addition, there were no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2019-Q2RestatedAnnual report
「No new business or other risks arose during the three months ended March 31. There were also no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2018-Q4RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the third quarter. In addition, there were no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2018-Q3RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the second quarter. In addition, there were no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2018-Q2RestatedAnnual report
「No new business or other risks arose during the three months ended March 31. There were also no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2017-Q4RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the third quarter. In addition, there were no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2017-Q3RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the second quarter. In addition, there were no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
市場ニーズとの乖離や研究開発投資の不成功による製品開発リスクについて、重要な変更がないとしている。 - FY2017-Q2RestatedAnnual report
「No new business or other risks arose during the three months ended March 31. There were also no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2017RestatedAnnual report
「There is no guarantee that these development investments will succeed or all lead to new products. If research and development themes diverge from market needs and are not accepted, they may affect our group’s operating results and financial position.」
研究開発投資の不成功や市場ニーズとの乖離による製品開発リスクを再確認している。 - FY2016-Q4RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the third quarter. In addition, there were no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2016-Q3RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the second quarter. In addition, there were no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
市場ニーズとの乖離による製品開発リスクについて、重要な変更がないとしている。 - FY2016-Q2RestatedAnnual report
「No new business or other risks arose during the three months ended March 31. There were also no material changes to the business and other risks described in the annual securities report for the preceding fiscal year.」
新製品開発・研究開発投資に関するリスクについて、前事業年度から重要な変更がないとしている。 - FY2016First statedAnnual report
「There is no guarantee that these development investments will succeed or all lead to new products. If research and development themes diverge from market needs and are not accepted, they may affect our group’s operating results and financial position.」
The group conducts planned development of new and existing products, cost reductions and basic research, while recognizing the uncertainty that investments may fail or products may not be accepted by the market.